Gilead pounced to buy cell therapy company Kite in August last year for just under $12 billion, shortly before the biotech firm gained approval for its CAR-T cancer therapy Yescarta. Now Gilead is ...

Kite’s CAR T-cell products are heading toward approval alongside those from Novartis, whose CTL019 therapy to treat acute lymphoblastic leukemia recently got two thumbs up from a US Food and Drug ...